BastR.C., KlugT.L., St JohnE.. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N Eng J Med1983; 309: 883–7.
2.
RuibalA., EncaboG., MirallesE.M.. CA 125 seric levels in non malignant pathologies.Bull Cancer (Paris)1984; 71: 145–8.
3.
RicolleauG., ChatalJ.F., FumoleauP., KremerM., Douvil-lardJ.Y., CurtetC.Radioimmunoassay of the CA 125 antigen in ovarian carcinomas: Advantages compared with CA 19.9 and CEA.Tumor Biology1984; 5: 151–9.
4.
KabawatS.E., BastR.C., BhanA.K., WelchW.R., KnappR.C., ColvinR.B.Tissue distribution of a coelomic epithelium-related antigen recognized by the monoclonal antibody OC 125.Lab Invest1983; 48: 42, Abstract.
5.
EerdekensM.W., NouwenE.J., PolletD.E., BriersT.W., De BroeM.E.Serum levels of hPLAP and CA 125 in benign and malignant disease and immunohistochemical evidence for CA 125 hepatic uptake.Br J Cancer1985; 52: 658, Abstract.